


December 25, 2013

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (ab-85)	CABOTEGRAVIR SODIUM
PRONUNCIATION	ka" boe teg' ra vir
THERAPEUTIC CLAIM	Treatment of HIV Infection; Prevention of HIV Infection
CHEMICAL NAMES	

1. Oxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazine-8-carboxamide, *N*-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11*a*-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, sodium salt (1:1), (3*S*,11*aR*)-
2. Sodium (3*S*,11*aR*)-8-[[[(2,4-difluorophenyl)methyl]carbamoyl]-3-methyl-5,7-dioxo-2,3,5,7,11,11*a*-hexahydrooxazolo[3,2-*a*]pyrido[1,2-*d*]pyrazin-6-olate

## STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>19</sub> H <sub>16</sub> F <sub>2</sub> N <sub>3</sub> NaO <sub>5</sub>
MOLECULAR WEIGHT	427.3
TRADEMARK	None as yet
SPONSOR	GlaxoSmithKline
CODE DESIGNATIONS	GSK1265744B S-265744B
<u>CAS</u> REGISTRY NUMBER	1051375-13-3

gbk